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Abstract
Background: Myofibroblasts, a derived subset of fibroblasts especially important in scar formation and wound
contraction, have been found at elevated levels in affected Dupuytren’s tissues. Transformation of fibroblasts to
myofibroblasts is characterized by expression of alpha- smooth muscle actin (a-SMA) and increased production of
extracellular matrix (ECM) components, both events of relevance to connective tissue remodeling. We propose that
increasing the activation of the cyclic AMP (cAMP)/protein kinase A signaling pathway will inhibit transforming
growth factor-beta1 (TGF-b1)-induced ECM synthesis and myofibroblast formation and may provide a means to
blunt fibrosis.
Methods: Fibroblasts derived from areas of Dupuytren’s contracture cord (DC), from adjacent and phenotypically
normal palmar fascia (PF), and from palmar fascia from patients undergoing carpal tunnel release (CTR; CT) were
treated with TGF-b1 (2 ng/ml) and/or forskolin (10 μM) (a known stimulator of cAMP). Total RNA and protein
extracted was subjected to real time RT-PCR and Western blot analysis.
Results: The basal mRNA expression levels of fibronectin- extra domain A (FN1-EDA), type I (COL1A2) and type III
collagen (COL3A1), and connective tissue growth factor (CTGF) were all significantly increased in DC- and in PF-
derived cells compared to CT-derived fibroblasts. The TGF-b1 stimulation of a-SMA, CTGF, COL1A2 and COL3A1
was greatly inhibited by concomitant treatment with forskolin, especially in DC-derived cells. In contrast, TGF-b1
stimulation of FN1-EDA showed similar levels of reduction with the addition of forskolin in all three cell types.
Conclusion: In sum, increasing cAMP levels show potential to inhibit the formation of myofibroblasts and
accumulation of ECM components. Molecular agents that increase cAMP may therefore prove useful in mitigating
DC progression or recurrence.
Background
Dupuytren’s contracture (DC) is a fibroproliferative dis-
ease of the hand’s palmar fascia, which can cause per-
manent and irreversible flexion contracture of the digits
[1]. It is the most common inherited disease of connec-
tive tissues in humans [2]. Although DC is not rare,
debate over its etiology has been ongoing since before
its modern-day description over 120 years ago [3]. DC is
known to result from changes occurring in the dermis
and palmar fascia [4]. Fibroblasts are the major cell
population associated with DC in all stages (both during
the formation of nodules and cords) and represent an
important target for therapeutic intervention. Impor-
tantly, differentiation of fibroblasts into myofibroblasts,
identified by their expression of alpha-smooth muscle
actin (a-SMA) [5-9], is considered to be responsible for
the development of typical clinical symptoms and offers
an opportunity for molecular intervention.
Myofibroblast formation is controlled by a variety of
growth factors, cytokines and even mechanical stimuli
[8,10]. Transforming growth factor-beta1 (TGF-b1)i s
the most important of these and has been demonstrated
in Dupuytren’s tissue using various techniques [11,12]
along with its receptors [4]. Berndt et al. [13] showed a
greater intensity of staining for TGF-b1 protein in prolif-
erative nodules and colocalization of TGF-b1 synthesis
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Furthermore, addition of TGF-b1 resulted in significant
up-regulation of cells staining for a-SMA in primary
cultures of fibroblasts derived from Dupuytren’sn o d u l e
and cord tissue. It therefore seems likely that this
growth factor plays a central function in the develop-
ment and progression of the disease.
Surgical intervention remains the mainstay of treat-
ment for DC, but there is a high recurrence rate after
surgery [14-16]. TGF-b1 release might also play a signifi-
cant role in the recurrence of the disease after surgical
treatment. The local trauma of surgical excision and the
resultant natural wound healing response will typically
lead to the release of growth factors which include
TGF-b1. Any residual tissue with a disease or pre-dis-
ease phenotype will be susceptible to stimulation, myofi-
broblast transformation, collagen synthesis and the
formation of recurrent disease. Some studies have corre-
lated recurrence of DC with the presence of myofibro-
blasts [17].
In this context, it is reasonable to hypothesize that a
means of counter-acting the signaling mechanisms of
TGF-b-mediated up-regulation of a-SMA and ECM
gene expression in Dupuytren’s tissue may provide
novel approaches to the therapy of DC disease. Accord-
ingly, we have focused our attention on cyclic AMP
(cAMP), a signal transduction mediator that may inter-
fere with TGF-b-initiated functions. The second mes-
senger cAMP regulates fibroblast physiology in many
tissues. Intracellular cAMP levels are the result of a bal-
ance between synthesis, which is regulated by G-pro-
tein-coupled receptors that stimulate (via Gs)o ri n h i b i t
(via Gi) adenylyl cyclase (AC), and degradation, which
o c c u r sv i ac y c l i cn u c l e o t i d ep h o s p h o d i e s t e r a s e( P D E ) .
Increases in cAMP influence cell growth, cell death, and
differentiated cell functions, primarily (although not
exclusively) by promoting phosphorylation of proteins
via the activation of cAMP-dependent protein kinase A
(PKA) [18]. PKA-mediated phosphorylation of cAMP-
response element-binding protein (CREB) and CREB-
mediated regulation of transcription via interaction with
cAMP-response elements is a major pathway that alters
cellular gene expression [19].
One mechanism by which cAMP may regulate fibro-
genicity is via interaction with the TGF-b signaling
pathway. Recent work suggests that activation of the
cAMP/PKA signaling pathway inhibits TGFb1-induced
collagen synthesis and myofibroblast formation in car-
diac and pulmonary fibroblasts [20,21]. These results
suggest that overproduction of cAMP may provide a
means to blunt fibrosis.
To our knowledge there have been no studies that
investigate the relationship between cAMP signaling and
TGF-b-mediated effects in DC disease. In this study we
sought to establish the baseline functioning of cAMP
and the effects of its elevation in DC-derived fibroblasts.
We specifically examined alpha-smooth muscle actin,
connective tissue growth factor (CTGF), as well as
important components of the extracellular matrix.
Methods
Cell Culture
Primary cultures of fibroblasts were obtained from the
surgically resected Dupuytren’s contracture samples
(DC), from matching specimens of normal appearing
palmar fascia in DC patients (PF), and from specimens
of normal palmar fascia of patients undergoing carpal
tunnel surgery (CT) as previously described [22,23]. All
samples were collected with the informed consent of the
patient and the study protocol conformed to the ethical
guidelines of the 1975 Declaration of Helsinki. All speci-
mens were collected with the approval of the Allegheny-
Singer Research Institute’s institution review board
involving Human Subjects (IRB protocol RC-4040) and
all the patients signed the written informed consent
under institutional review board approval. The cultures
were maintained in MEM-a medium (Invitrogen Cor-
poration, Carlsbad, CA) supplemented with 10% fetal
bovine serum (FBS, Gemini Bioproducts, West Sacra-
mento, CA) and 1% antibiotic-antimycotic solution
(Sigma, St Louis, MO). All cultures were used at passage
levels between 3-6 with no changes evident in cell
morphology.
CT-, PF-, and DC- derived fibroblasts were plated
onto 6-well Falcon tissue culture plates and grown until
80% confluence. Cells were quiesced for 24 hours in
MEM-a medium supplemented with 0.1% dialyzed
fetal bovine serum (Gemini Bioproducts) and 1% anti-
biotic-antimycotic solution. After 24 hours the cells
were then treated or not with TGF-b1 (2 ng/ml) (Pepro-
tech, Inc. Rockyhill, NJ) and/or forskolin (Sigma) (10
μM) and incubated for 37°C for 24 hours. Cells were
then washed with phosphate buffered saline (PBS) and
lysed using M-PER obtained from Thermo Fisher Scien-
tific (Rockford, IL) for protein extraction and RLT-lysis
buffer (Qiagen Inc.Valencia, CA) for RNA isolation
according to the manufacturer’s instructions. RNA qual-
ity was assessed by A260/280 ratio using an ND-1000
spectrophotometer (Nanodrop Technologies Inc, Wil-
mington, DE) and by capillary electrophoresis with the
Agilent 2100 bioanalyzer (Agilent technologies, Inc. Palo
Alto, CA). At least three independent primary cell cul-
tures of CT-, PF- and DC- derived fibroblasts were used
in experiments involving treatment with TGF-b1 or for-
skolin. Six independent sets of CT-, PF-, and DC-
derived fibroblasts were used in establishing the basal
mRNA expression of specific extracellular matrix (ECM)
proteins.
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Total RNA isolated (RNeasy Micro Kit, Qiagen Inc.,
Valencia, CA) from untreated DC -, PF- and CT-derived
fibroblasts was subjected to real time RT-PCR to deter-
mine the relative mRNA expression levels at baseline for
fibronectin (FN1-EDA), type I collagen (COL1A2), type
III collagen (COL3A1) and connective tissue growth fac-
tor (CTGF). RNA isolated from cells treated with TGF-
b1, forskolin, and with both agents was also subjected to
real time RT-PCR to determine the changes in the
mRNA levels of a-SMA (ACTA2), FN1-EDA, COL1A2,
COL3A1 and CTGF.
Real-time RT-PCR was performed using kits obtained
from Applied Biosystems (Foster City, CA) that utilize
FAM™Taqman
®MGB probes and a Taqman
® Universal
PCR Master Mix. Assays were performed on the above
noted gene products using human GAPDH as an endo-
genous normalizing control. Reverse transcription was
performed on 30 ng of total RNA with random primers
(100 ng), gene specific primer for FN1-EDA (10 pmole)
and with M-MLV-reverse transcriptase (Invitrogen Cor-
poration, Carlsbad, CA). The primers (forward primer
5’-TAAAGGACTGGCATTCACTGATGT-3’;r e v e r s e
primer - 3’-GTGCAAGGCAACCACACTGA-5’)a n d
probe (5’6 FAM-CCCTGAGGATGGAATCCATGAGC-
TATTCC-TAMRA 3’) used for human FN1-EDA [Gen-
Bank: X07718] were designed using Primer Express
software (Applied Biosystems). Primers were obtained
from Integrated DNA Technologies (Coralville, IA) and
Taqman probes were purchased from Applied Biosys-
tems. In all assays the primer sets were first tested to
verify that amplimers of the expected molecular weight
resulted before their employment in real time RT-PCR.
Subsequent PCR amplification and detection of tem-
plate was carried out using Applied Biosystems tran-
script-specific assays including: COL1A2 (ID-
Hs01028971_m1), COL3A1 (ID-Hs00943793), ACTA2
(ID- HS00426835_g1) and CTGF (ID-Hs00170014_m1)
using 15 ng of cDNA and 20x final concentration of
Gene Expression Mix, which contains both forward and
reverse primers adjusted to final volume of 15.0 μl.
Identical reaction mixes were prepared with human
FN1-EDA primers and probes. The reaction set up and
the thermal cycling protocol were as previously
described (23). Using the comparative critical cycle (Ct)
method the expression levels of the target genes were
normalized to the GAPDH endogenous control (ID-
HS99999905_m1) and the relative abundance was calcu-
lated. Data were analyzed using the 7900 HT SDS soft-
ware version 2.1 provided by Applied Biosystems.
Immunoblotting
Proteins extracted were subjected to Bradford assay to
determine the protein concentration. Equal quantities of
proteins were separated on SDS-PAGE, transferred to a
Whatman™ Protran pure nitrocellulose immobilization
membrane (GE Health Care, Piscataway, NJ) and probed
with antibodies specific to a-SMA (Abcam, Cambridge,
MA) and fibronectin (Santacruz Biotechnology, Inc.
Santa Cruz, CA) using GAPDH (Abcam, Cambridge,
MA) as loading control. The membranes were conju-
gated with HRP-labeled secondary antibody, and the sig-
nals were detected using SuperSignal
® West Femto
Trial Kit Prod #34094 (Thermo Scientific, Rockford, IL).
The intensity of the protein bands was quantitated using
NIH Image J 1.44p, available in the public domain at
http://imagej.nih.gov/ij.
Statistical Analysis
Statistical analyses were performed using two-way
ANOVA utilizing GraphPad Prism 5 for Windows Ver-
sion (5.04) from Graph Pad Software Inc. Utilizing the
same program Bonferroni post-test to compare replicate
means by row was also performed to determine the p
values. P value less than 0.05 was considered significant.
Results
Basal mRNA expression levels of ECM proteins were
significantly increased in Dupuytren-derived fibroblasts
We first examined the message levels of ECM proteins,
namely COL1A2, COL3A1, FN1-EDA and CTGF, a
matricellular protein, by qRT-PCR. Our results identi-
fied increased mRNA expression levels of all the above
gene products in DC- derived fibroblasts relative to CT-
derived fibroblasts (Figure 1a, b, c, d). Interestingly, PF-
derived fibroblasts express these ECM components in a
similar fashion to fibroblasts from active disease, sug-
gesting that even apparently normal fascia in DC
patients may harbor an incipient disease phenotype.
Forskolin inhibited the TGF-b1 stimulation of a-SMA
mRNA and protein
Our previous findings have demonstrated an elevation at
baseline of a-SMA mRNA and protein levels in DC- in
comparison to CT- and PF-derived fibroblasts (Satish et
al., manuscript in preparation). The present study shows
that addition of TGF-b1 greatly augments the levels of
a-SMA mRNA in CT-, PF- and DC- derived fibroblasts.
To determine if increased levels of cAMP could reduce
the TGF-b1 induced levels of a-SMA, forskolin, a well-
established adenylyl cyclase (AC) activator and an indu-
cer of cAMP in fibroblasts [20,24,25] was utilized. We
found that by increasing cAMP levels there was a sub-
s t a n t i a lr e d u c t i o ni nT G F - b1 induced mRNA levels of
a-SMA in DC- derived fibroblasts compared to TGF-b1
treatment alone. Although apparent reductions in TGF-
b1-induced a-SMA mRNA levels were also observed in
CT-derived fibroblasts and PF-derived fibroblasts
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these cAMP effects was significantly less than in DC-
derived cells (Figure 2a). Similar significant reductions
in TGF-b1-induced a-SMA protein levels were seen in
all three-cell types by Western blot (Figure 3a-d). For-
skolin by itself did not have any significant effect on a-
SMA mRNA or protein levels in any cell type. These
results strongly suggest that myofibroblast formation (as
evidenced by a-SMA accumulation) can be significantly
inhibited in DC- derived cells by increasing cAMP
levels.
Forskolin reduced the TGF-b1 induction of fibronectin
mRNA and protein
Extracellular matrix deposition likely plays a crucial role
in the fibrosis noted in DC, and previous studies have
observed increased deposition of an oncofetal isoform of
fibronectin (IIICS spliced variant) in DC lesional tissues
and in DC-derived primary cell cultures [22]. In this
s t u d yw ee x a m i n e dF N 1 - e x t r ad o m a i nA( E D A ) ,a st h i s
isoform has shown differential expression between fibro-
tic versus scarless healing seen in mucosal and skin
wound healing [26]. Forskolin treatment alone had no
significant effect on FN1-EDA mRNA levels in any of
our three cell types (Figure 2b), nor were fibronectin
protein levels affected in CT- and PF-derived cells, but
we did observe a significant decrease in fibronectin pro-
tein in DC- derived fibroblasts on forskolin treatment
by Western blot (Figure 3a-c, e), the mechanism for
which may be post-transcriptional.
We found that forskolin inhibited TGF-b1-induction
of fibronectin mRNA to a similar degree in CT-, PF-
and DC- derived fibroblasts when measured against
TGF-b1 treatment alone (Figure 2b). This is in contrast
to a-SMA, where DC-derived cells were uniquely and
especially susceptible to this forskolin effect. Fibronectin
protein levels in all three cell types also showed relative
decrease when forskolin was added compared to TGF-
b1 alone (Figure 3a-c, e).
Forskolin inhibited the TGF-b1 induction of CTGF mRNA
in PF- and DC- derived cells but not CT-derived cells
We next determined the effect of increased cAMP levels
on another TGF-b1 target gene, CTGF. Since TGF-b
m a yi n d u c eC T G Ft h r o u g hs e v e r a lp a t h w a y s ,i n c l u d i n g
S M A D ,r a s / r a f / M E K / E R K ,E t s - 1 ,J N K ,a n dp r o t e i n
kinase C, CTGF has long been thought to be an impor-
tant mediator of its fibrotic effects [27-30]. The TGF-b1
induction of CTGF mRNA increase was substantially
reduced by combined incubation with forskolin in PF-
Figure 1 Basal mRNA expression of ECM proteins was significantly elevated in DC-derived fibroblasts. Real time RT-PCR was performed
on RNA extracted from 6 independent primary cultures derived from CT-, PF- and DC- tissues to determine the mRNA expression levels of
COL1A2 (a), COL3A1 (b), FN1-EDA (c), and CTGF (d). Values are means ± SEM of three independent experiments performed in duplicate.
Statistical analyses were performed using two-way ANOVA.
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(Figure 2c). As with a-SMA, these results again suggest
that the biology of fibroblasts from DC patients is exqui-
sitely sensitive to the mitigating actions of cAMP.
Forskolin reduced the TGF-b1 stimulation of Type I and
Type III collagen
We next investigated the effect of increased cAMP (via
forskolin treatment) on collagen expression as TGF-b is
a known stimulator of collagen production [31]. We
specifically examined if increased cAMP levels can abro-
gate TGF-b1 induction of type I (a-2 chain; COL1A2)
and type III collagen (a-1 chain; COL3A1) expression.
Forskolin alone did not have any significant effect on
the relative levels of COL1A2 and COL3A1 mRNAs in
any of the three cell types. Forskolin did, however, sup-
press the TGF-b1 induction of COL1A2 and COL3A1
mRNAs in CT-, PF- and DC -derived fibroblasts (Figure
2d, e). Of note, the degree of inhibition seen when
TGF-b1 was co-incubated with forskolin was signifi-
cantly greater in DC -derived cells than in the CT- or
PF-cells. Since increased collagen deposition is a hall-
mark of DC disease, these results again suggest that
mechanisms to elevate cAMP may be useful adjunctive
therapies to counteract the fibrotic phenotypes of DC
cells.
Discussion
Dupuytren’s contracture, fibrosis in the palmar fascia of
the hand, is a fibroproliferative disorder that can impose
severe functional damage eventually leading to disability
of the hand in affected individuals [32]. Efforts have
been made to control the fibrosis seen in DC using var-
ious non-surgical treatment strategies but with limited
success [33]. Injectable collagenase clostridium histolyti-
cum [34] to treat DC shows potential promise but its
clinical application has thus far elicited a varied
response among hand surgeons. Alternative treatment
options including non-surgical molecular therapeutic
agents to prevent progression and recurrence of DC dis-
ease are still wanting.
Because myofibroblast formation and activity have
been linked to the etiology of both primary and recur-
rent DC, molecular interventions that interfere with
myofibroblastic functions may offer a novel avenue of
therapy. A number of such interventions have been pro-
posed and essayed. Glucocorticoids have been shown to
increase apoptosis of Dupuytren’s-associated fibroblasts,
and to reduce the abundance of TGF-b1 and fibronectin
CS1 in myofibroblast-populated stroma in DC nodules
injected with depomedrone [35,36]. Repeated intrale-
sional injection of DC nodules (not cords) with triamci-
nolone did show some regression of the nodules [37]
but some 50% of patients developed recurrence or
Figure 2 Forskolin effectively reduced TGF-b1 stimulation of a-
SMA, FN1-EDA, CTGF, COL1A2 and COL3A1. Fibroblast cultures
from CT-, PF- and DC- tissues were left untreated or were
stimulated with forskolin (10 μM) in the presence or absence of
TGF-b1 (2 ng/ml). Twenty-four hours later, mRNA expression levels
of a-SMA (a), FN1-EDA (b), CTGF (c), COL1A2 (d) and COL3A1 (e)
were analyzed by real time RT-PCR. In each experiment at least
three independent cultures obtained from all the three cell types
were used. Values are means ± SEM of six independent studies
performed in duplicate. Statistical analyses were performed using
two-way ANOVA.
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derived fibroblasts. CT-, PF- and DC-derived fibroblasts (a, b, c) grown on 6-well culture dishes were stimulated with forskolin (10 μM), TGF-b1
(2 ng/ml), with both agents, or were left untreated for 24 hours in MEM-a medium containing 0.1% dialyzed FBS. Whole cell lysates were
collected after 24 hours and the samples were processed for Western immunoblotting with specific antibodies for a-SMA and FN1-EDA (20 μg/
lane). Specificity of the modulation and identical protein loading was confirmed with a loading control GAPDH antibody. Densitometry analysis
was done on protein bands obtained from three independent experiments performed in triplicate using two independent primary cultures of
CT-, PF- and DC-derived fibroblasts (Figure 3d and 3e). A representative immunoblot is shown here.
Satish et al. BMC Musculoskeletal Disorders 2011, 12:113
http://www.biomedcentral.com/1471-2474/12/113
Page 6 of 9progression of the disease within the window of the
study. Whether such an approach would succeed in
more advanced disease with actual cord formation is
unclear.
Another agent that acts against myofibroblasts that
has been used in DC is 5-fluorouracil (5-FU). Treatment
of DC-derived fibroblasts with 5-FU inhibited their pro-
liferation and their differentiation to myofibroblasts [38].
However, clinical use of 5-FU at the time of surgery
resulted in no difference between treated and untreated
digits as determined by joint angle measurements [39],
leaving its clinical utility open to question.
It has been observed in rat cardiac fibroblasts and in a
human pulmonary fibroblast-derived cell line that eleva-
tion of cAMP can inhibit cellular proliferation and dif-
ferentiated functions (such as collagen synthesis). These
observations suggested that a similar approach might
favorably alter fibroblast/myofibroblast behavior in the
setting of Dupuytren’s contracture. We therefore sought
to determine if increased cAMP levels could inhibit
TGF-b1-induced myofibroblast formation (as indicated
by a-SMA accumulation) and ECM production in DC-
derived cells. TGF-b1 was chosen as a test stimulatory
cytokine as it has been implicated in the pathogenesis of
DC [2,4,40].
Multiple interesting observations have arisen from
these experiments. When assaying for basal levels of
expression of a-SMA and ECM proteins in our three
cell types, it is clear that PF-derived cells more closely
resemble DC-derived cells than control CT-derived cells
in all four gene products tested. This suggests that,
although obtained from phenotypically normal fascia,
PF-derived cells may already exhibit a disease phenotype
at the cellular level. Such an observation is consistent
with our total expressomic analyses of DC- and PF- ver-
sus CT-derived fibroblasts, wherein we find that global
gene expression patterns of PF-cells closely resemble
(but are not identical to) DC-derived cells and vary
sharply from CT-derived cells (Satish et al., manuscript
in preparation).
We also found that TGF-b1, as expected, increased
expression levels of all gene products assayed signifi-
cantly, whereas cAMP elevation (as induced by forskolin
treatment) alone had minimal effect. cAMP was, how-
ever, in all instances able to dramatically blunt the
effects of TGF-b1. DC-derived cells were particularly
susceptible to cAMP action, generally exhibiting more
inhibition of gene expression by cAMP action than PF-
or CT-cells. These observations suggest that agents to
elevate cAMP may well be able to suppress the differen-
tiation of DC-fibroblasts to a myofibroblast phenotype,
and to mitigate the abnormal ECM deposition that
would then typically ensue. Although forskolin (or other
similar agents) may be impractical to deliver directly to
DC-affected tissues over the long periods of time in
which the disease develops or progresses, we postulate
that molecular therapeutic approaches administering
activated adenylyl cyclase, possibly by a gene therapy
approach, may accomplish the same effects. Successful
use of adenylyl cyclase to inhibit myofibroblast forma-
tion and function has been demonstrated in cardiac and
pulmonary cells [20,21].
A particular point of interest in this study is the
examination of the behavior of CTGF in our three cell
types. CTGF has been described as a co-factor to TGF-b
by enhancing ligand-receptor binding in activated cells
[41]. Studies in various cell populations have also
demonstrated roles for CTGF in the TGF-b-dependent
induction of fibronectin, collagen and tissue inhibitor of
metalloproteinase-1 (TIMP-1) [42-44]. A recent study
by Sisco et al. [45] showed that antisense inhibition of
CTGF could limit hypertrophic scarring in vivo without
affecting the outcome of wound closure. To our knowl-
edge this report for the first time demonstrates
increased basal expression levels of CTGF in PF- and in
DC-derived fibroblasts compared to CT-derived cells,
and this relative increase is enhanced by addition of
TGF-b1. Further, we also find that elevated cAMP levels
most successfully reduce this increased CTGF mRNA
expression in DC-derived fibroblasts. This report thus
points to a potential role for CTGF in the etiopathology
of DC, and suggests that measures to target its expres-
sion or function (including agents that elevate cAMP)
may usefully limit fibrosis in Dupuytren’s contracture.
The observations reported herein do not directly iden-
tify the precise mechanisms by which increased cAMP
levels inhibit myofibroblast formation. Recent data indi-
cate that cAMP acts in a PKA-dependent manner to
inhibit TGF-b/Smad signaling and gene activation by
disruption of transcriptional cofactor binding in human
keratinocytes [46]; it is possible that similar mechanisms
are at work in DC-fibroblasts, and are being investi-
gated. Moreover, we are in the process of delineating
the migratory and contractile behavior of DC-derived
fibroblasts when cAMP levels are increased. Demonstra-
tion of a change in these mechanocellular properties
would provide even more evidence of the utility of a
cAMP-based approach as an anti-fibrotic measure in
Dupuytren’s contracture.
Conclusion
In summary, increasing cAMP levels show potential to
inhibit the formation of myofibroblasts and accumula-
tion of ECM components. Molecular agents that
increase cAMP may therefore prove useful in mitigating
DC progression or recurrence.
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